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Abstract
The syndrome of periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA syndrome) is the
most common cause of periodic fever in childhood. The current pharmacological treatment includes corticosteroids,
which usually are efficacious in the management of fever episodes, colchicine, for the prophylaxis of febrile episodes,
and other medication for which efficacy has not been proven so far. Tonsillectomy is an option for selected patients.
Usually PFAPA syndrome resolves during adolescence, but there is increasing evidence that this condition may persist
into adulthood.
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Background
The syndrome of periodic fever, aphthous stomatitis,
pharyngitis and cervical adenitis (PFAPA syndrome) is
the most common cause of periodic fever in childhood
and it was first described in1987 by Marshall et al. [1]. It
is characterized by episodes of fever lasting for 3–6 days
with recurrence every 3–8 weeks, associated with at least
one of three main symptoms: aphthous stomatitis, cervical
adenitis, and pharyngitis [2]. Disease onset is usually be-
fore the age of 5 and generally resolves by adolescence. Pa-
tients are asymptomatic between episodes and show
normal growth. Proposed contributors to pathogenesis in-
clude infection, abnormal host immune responses, or a
combination of both [3, 4]. PFAPA syndrome is an im-
mune mediated disease characterised by a cytokine dys-
function [3, 5]; moreover, the strong familial clustering
suggest a potential genetic origin of the syndrome [6, 7].
The presence of variants in inflammasome related genes,
mostly in NLRP3 and MEFV, suggest a possible role of
these genes in PFAPA pathogenesis [7–9]. However, none
of these variants alone seem to be relevant for the disease
etiology, suggesting an oligenic or polygenic background.
Currently the diagnosis of PFAPA is based on clinical
criteria [2] (Table 1), but these criteria have not been
validated in a cohort of patients. Moreover, Gattorno
et al. found that a significant number of patients with
monogenic periodic fevers also meet the diagnostic cri-
teria for PFAPA syndrome [10], highlighting the poor
specificity of the current classification criteria. There-
fore, patients should be screened clinically or genetically
for other known periodic syndromes before assigning
the diagnosis of PFAPA.
PFAPA syndrome has favourable natural history. There
is no evidence that medical treatment can modify the
outcome, but it can be efficacious for treating the epi-
sodes (Table 2). Inducing a rapid remission of episodes
is important to improve the quality of life for patients
and their families. In this paper we review the current
treatment strategies for PFAPA and what is known about
the outcome of this syndrome.
Symptomatic treatment during flares
Non-steroidal anti-inflammatory agents and anti-pyretics
have shown poor results in resolving symptoms of PFAPA
syndrome. Glucocorticoids are highly effective in aborting
the attacks, but there are limited data on the effectiveness
of any preventive medication in PFAPA.
Rapid resolution of flare: glucocorticoids
Orally given glucocorticoids relieve symptoms of PFAPA
in a dramatic fashion [11–15].
A single dose of prednisone (1– 2 mg/kg) or beta-
methasone (0.1–0.2 mg/kg) given at the onset of an epi-
sode can dramatically abort fever attacks in a few hours.
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Aphtous stomatitis, however, can take longer to resolve
[2, 16]. If one dose is not effective in inducing resolution
of flare, a second dose may be given the following day.
In the largest PFAPA cohort described so far, Hofer
et al. found that 147 out of 301 patients were treated
with steroids. They observed a rapid resolution of fever
episodes after a single dose of steroids in 93/147 patients
(63 %), whereas 46 (32 %) showed a partial response and
only 8 (5 %) were non-responders [16]. Data from the
EUROFEVER registry confirm the widespread use of ste-
roids for disease flare, with 81 out of 92 patients treated
at the onset of attacks, and their effectiveness in 73 pa-
tients (90 % of those treated) [13]. Wurster et al. de-
scribed a cohort of 60 patients in which 44 patients were
treated with steroids during episodes and the treatment
was effective in 37 (84 %) [17].
Tasher et al., in their uncontrolled series, described
that a single low dose of prednisone (mean 0.6 mg/kg
per day) was effective to rapidly resolve the fever episode
within an average of 10 h in 51 out of 54 PFAPA patients
[18]. The effectiveness of a single low dose of prednisone
was confirmed in a preliminary study performed by
Yazgan et al., that did not show any statistical signifi-
cance in efficacy between a dose of 2 mg/kg/day versus a
dose of 0.5 mg/kg/day respectively in 40 and 46 PFAPA
febrile attacks [19].
The usefulness of steroids is limited by the fact that
the interval between episodes may be shortened in 25–
50 % of cases [15, 20, 21]. Moreover, the administration
of corticosteroids does not prevent future fever attacks.
Side effects are rare; the most commonly reported by
Tasher et al. is restlessness. Nevertheless, parents of
PFAPA patients are often concerned about the possibil-
ity of systemic side effects, and this fact may result in
poor compliance.
Finally, the steroid response may be useful in distin-
guishing attacks of PFAPA from familial Mediterranean
fever (FMF) or other hereditary periodic fever syndromes
(HPF) [11, 12] and can be used as an additional criterion
for diagnosis [16]. In fact, HPF attack, except for periodic
fever associated with Mevalonate Kinase Deficiency (MKD),
usually doesn’t show a dramatic response to a single dose
of steroids like PFAPA.
Reduction of flare frequency: colchicine
The precise mechanism of action of colchicine in reducing
inflammation is unknown. Colchicine binds to tubulin,
forming a tubulin-colchicine complex. This complex can
change the structure and the function of the cytoskeleton,
thereby influencing neutrophil and lymphocyte migration
and adhesion [22]. The rationale for the use of colchicine
as a prophylactic treatment for PFAPA is based primarily
on clinical and laboratory similarities between FMF and
PFAPA and the long-term experience with this drug in the
treatment of FMF. For these reasons, when colchicine is
effective in PFAPA patients, an alternative diagnosis of
FMF has to be considered.
In a 6-month open label, randomized, controlled study,
Aviel et al. showed a significant increase in intervals be-
tween attacks in 8 PFAPA patients on colchicine therapy
compared with 10 patients treated only with corticoste-
roids. Among the 18 treated patients treated, 8 carried
FMF mutations; 6/8 in the colchicine group and 2/10 in
the steroid group [23].
Padeh et al. described 10 PFAPA patients previously di-
agnosed as FMF patients; 6 out of 10 were heterozygous
for an MEFV gene mutation (M694V), but had clinical
features consistent with PFAPA. Colchicine prescribed to
these patients had only a partial effect and was discontin-
ued [24].
In an open label study, Tasher et al. investigated the ef-
ficacy of colchicine treatment in 9 PFAPA patients with
frequent episodes (≤14 days interval). Two patients out
of nine were compound heterozygotes for multiple MEFV
mutations but exhibited typical features of PFAPA. Colchi-
cine treatment significantly increased the interval between
the episodes in eight of these patients [25].
Dusser et al. performed a retrospective, multicenter
study in which they reviewed 20 PFAPA patients treated
with colchicine. Half of the patients were heterozygous
for a pathogenic mutation in the MEFV gene. The au-
thors found that nine patients had no more or suffered
half as many episodes during colchicine treatment. No
Table 1 Diagnostic criteria used for PFAPA
I. Regularly recurring fevers with an early age of onset (<5 years of age)
II. Constitutional symptoms in the absence of upper respiratory infection
with at least 1 of the following clinical signs : a) aphtous stomatitis,
b) cervical lymphadenitis, c) pharyngitis
III. Completely asymptomatic interval between episodes
IV. Normal growth and development
Table 2 Pharmacological treatment for PFAPA syndrome
Treatment of the episodes
Dose Remarks
Prednisone 0.5–2 mg/Kg, orally the
first day of fever
Possible to repeat on
day 2 if fever persists
Betametasone 0.2 mg/Kg, orally the
first day of fever
Possible to repeat on
day 2 if fever persists
Prophylactic Treatment
Dose Remarks
Colchicine 0.5–1 mg/daily, orally Gastro-intestinal
side effects
Cimetidine 20–40/mg/Kg/daily, orally Poor efficacy
Anakinra 1 mg/Kg, sc the first
and second day of fever
Cost-effectiveness
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significant differences in demographic/clinical variables or
the rate of MEFV mutation carriage were found between
the two groups (responder and non-responder) [26].
Due to the small size of the samples, Aviel and Dusser
didn’t find variables that could predict responsiveness to
colchicine. Because of the good response of FMF to col-
chicine, PFAPA patients heterozygous for MEFV muta-
tions may respond better to this drug, but differences in
the response to colchicine between carriers and non-
carriers of the MEFV mutation have not been demon-
strated so far.
Colchicine is usually well tolerated. The most common
adverse reactions to colchicine are gastrointestinal (ap-
proximately 10 %). This effect may be partially explained
by induction or worsening of lactose intolerance by this
medication [25], though multiple mechanism may be
responsible.
These findings suggest that colchicine may be an ef-
fective second line treatment to prevent frequently re-
current fever episodes in PFAPA patients, in particular if
prednisone is decreases the interval between episodes.
Other medications
Cimetidine, a common H2 antagonist, has immune-
modulating properties, inhibiting chemotaxis and T-cell
activation. Cimetidine was suggested as an effective
prophylactic treatment for PFAPA in 1992 by Feder [27].
Thomas et al. reported a 43 % efficacy of cimetidine in a
group of 28 patients according to data based on tele-
phone recall [2]. Wurster et al. found that in their co-
hort, cimetidine was effective as symptomatic therapy in
6 out of 25 (26 %) patients while in the remaining pa-
tients the treatment was ineffective [17]. None of the 92
PFAPA patients from the EUROFEVER registry, and
none of the 42 patients from the Norwegian cohort,
were treated with cimetidine, underlining the fact that in
recent years this treatment is less prescribed [13, 21].
Moreover, there are no randomized controlled trials sup-
porting benefits of cimetidine to date.
IL-1 plays a central role in PFAPA pathogenesis, as
demonstrated by Stojanov et al. [3]. In a small cohort of
5 children with PFAPA syndrome a single dose of ana-
kinra, on the second day of fever, dramatically improved
both clinical picture and laboratory parameters [5].
Cantarini et al. described a case of a 27-year-old man
resistant to conventional therapy (corticosteroids, colchi-
cine, and tonsillectomy) who was treated with subcuta-
neous injection of anakinra, with a complete resolution
of fever attacks [28]. Despite these interesting reports,
the use of IL-1 blockers for PFAPA treatment is re-
stricted to selected cases due to the lack of both ran-
domized trials as well as coverage by health care plans.
Vitamin D has recently gained attention as a possible
regulator of inflammation due to the finding that low
Vitamin D levels are associated with some inflammatory
disorders [29]. In recent years two studies investigated a
possible role of vitamin D in PFAPA syndrome. Mahamid
et al. found a significant correlation between PFAPA and
vitamin D deficiency, demonstrating a significant differ-
ence in vitamin D levels between 22 PFAPA patients and
20 control subjects [30]. Stagi et al. confirmed this finding
and demonstrated a significant reduction in the number
of febrile episodes and a shortening of mean duration of
episodes in patients after vitamin D supplementation
(400 IU 25-hydroxyvitamin D daily during wintertime)
[31]. However, on the basis of these data it is not possible
to conclude that vitamin D is effective in treating or pre-
venting PFAPA syndrome, and prospective studies on
large cohorts of patients and randomized clinical trials are
needed.
Adenotonsillectomy
The role of tonsillectomy in PFAPA syndrome remains
controversial. In 1989 an initial study reported efficacy
of tonsillectomy in 4 PFAPA patients [32]. Afterwards, a
large variability in success rate was reported in other
studies. In a randomized controlled trial, Renko et al.
compared the effectiveness of tonsillectomy versus no
intervention in 26 patients diagnosed with PFAPA (14
underwent tonsillectomy and 12 were observed without
surgery) [33]. PFAPA syndrome resolved immediately in
all 14 patients randomized to tonsillectomy; in contrast,
the syndrome resolved spontaneously within 6 months
in 6/12 patients who did not receive tonsillectomy. How-
ever, in this cohort, 50 % of the tonsillectomy group and
77 % of the control group had recurrent fever as the
only cardinal symptom and thereby did not actually fulfil
diagnostic criteria for PFAPA.
Garavello et al. performed a prospective randomized
controlled trial with 39 PFAPA patients; 19 underwent
adenotonsillectomy and 20 were treated with medical
therapy [34]. Six months after surgery, resolution of epi-
sodes was observed in 12/19 cases (63 %) and at 18 months
follow up they observed complete resolution of episodes
in this group within 1 year. In contrast to the findings of
Renko et al., only 1 patient in the control group showed
spontaneous resolution.
A prospective study by Licameli et al. evaluated the
long-term efficacy of adeno-tonsillectomy in 102 pa-
tients with PFAPA followed for longer than 6 months
after surgery (mean 43 months): Ninety-nine experi-
enced complete resolution immediately aſter surgery and
1 after 6 months. Of the 2 remaining patients, 1 contin-
ued having fever episodes, while 1 was further investi-
gated and subsequently diagnosed with MKD [35].
Although other reports exist, a recent Cochrane re-
view [36] points out that only two randomised con-
trolled trials, conducted on small cohorts of patients,
Vanoni et al. Pediatric Rheumatology  (2016) 14:38 Page 3 of 5
demonstrate the effectiveness of the tonsillectomy in
treating children with PFAPA. Moreover, these studies
show some differences in outcome after surgery, prob-
ably due to the heterogeneity of the study population,
the choice of different diagnostic criteria, the different
type of intervention (i.e., tonsillectomy versus adenoton-
sillectomy), and the different follow up schedule aſter
surgery. It is not proven that to combining adenoidect-
omy with tonsillectomy can improve the outcome, com-
pared to tonsillectomy alone.
Considering the favourable evolution of PFAPA and
the possible post-surgical complications, adenotonsillect-
omy should be proposed to selected patients, for ex-
ample when the interval between attacks is very short in
which corticosteroid treatment is not appropriate.
Outcome
PFAPA syndrome is considered a self-limited disease
that generally resolves spontaneously before adolescence
[16, 17]. Patients’ growth and development are normal
and no long-term consequences have been described [2].
Wurster et al. followed a cohort of 59 patients for a
period ranging between 12 and 21 years. Fifty patients
experienced spontaneous symptom resolution without
relapse; only 9 maintained typical cardinal PFAPA symp-
toms, though fever was less frequent [17]. They also ob-
served a significantly higher frequency of family history
of periodic fever in the patients with persistent symp-
toms in adulthood.
In a Norwegian cohort, thirty-seven children were
followed until resolution with a median follow up of
18.7 months (range 7.2– 75.7). The median age at the time
of resolution was 52.1 months. Interestingly, eight children
experienced a relapse after a febrile attack-free period of
more than 6 months. The median duration of the attack-
free periods leading up to the relapse was 20 months [21].
Other studies, with a shorter follow-up, reported a
spontaneous resolution in only 20–32 % of the patients
[12, 24, 25].
Berkun et al. described a cohort of 124 PFAPA patients,
of which 65 showed a single MEFV mutation. PFAPA at-
tacks in MEFV carriers were shorter, compared with pa-
tients without mutations, and the frequency of their
attacks and oral aphthae were also lower. This may sug-
gest that mutations in causative genes of other monogenic
periodic fevers may modify the disease course [37].
As shown in different studies, PFAPA may have its onset
in adulthood as well [11, 16, 38]. To date, no long-term
outcome data are available for adult patients diagnosed
with PFAPA syndrome, so it is not known whether adults
with PFAPA syndrome may spontaneously undergo clin-
ical remission. Based on a review of the recent literature,
tonsillectomy does not seem to be a valid option in these
patients [39]. There are reports describing adult PFAPA
patients with a history of tonsillectomy during childhood
due to recurrent febrile tonsillo-pharyngitis, with subse-
quent disease free period of several years. These findings
may suggest that tonsillectomy is efficacious in inducing
a temporary remission but that the effect may be transi-
ent [40].
Conclusions
PFAPA syndrome is a relatively common condition in
childhood, but it can also persist into adulthood. The
disease usually has a benign and self-limiting course.
Treatment with single doses of glucocorticoids is effect-
ive in controlling the fever episodes. Colchicine may be
an interesting option for patients with frequent episodes.
Tonsillectomy should be reserved for selected patients
refractory to medical treatment and children with long-
lasting disease affecting the quality of life.
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